Overview

Study of ALTO-300 in MDD

Status:
Recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Phase:

Phase 2

Details

Lead Sponsor:

Alto Neuroscience